DOCSLIB.ORG

Download Thesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Thesis This electronic thesis or dissertation has been downloaded from the King’s Research Portal at https://kclpure.kcl.ac.uk/portal/ Roles of TRPM8 and TRPM3 in sensory transduction Quallo, Talisia Esme Awarding institution: King's College London The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without proper acknowledgement. END USER LICENCE AGREEMENT Unless another licence is stated on the immediately following page this work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ You are free to copy, distribute and transmit the work Under the following conditions: Attribution: You must attribute the work in the manner specified by the author (but not in any way that suggests that they endorse you or your use of the work). Non Commercial: You may not use this work for commercial purposes. No Derivative Works - You may not alter, transform, or build upon this work. Any of these conditions can be waived if you receive permission from the author. Your fair dealings and other rights are in no way affected by the above. Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 25. Sep. 2021 Roles of TRPM8 and TRPM3 in sensory transduction Thesis submitted for the degree of Doctor of Philosophy King’s College London Talisia Esme Quallo Wolfson Centre for Age-Related Diseases School of Biomedical Health Sciences King’s College London 2010-2014 1 Abstract Primary afferent neurons are equipped with sensory transduction channels which allow the conversion of physical and chemical stimuli into electrical signals. TRP channels are a heterogeneous superfamily of largely non-selective cation channels, which have been implicated in a myriad of sensory transduction mechanisms from the detection of temperature to the sensation of touch. Many TRP channels are key targets for the study of pain physiology due to their polymodal activation and expression in small diameter, unmyelinated sensory fibres. The aim of my project was to examine the roles of TRP channels in sensory transduction mechanisms. Three results chapters focusing on three different TRP channels are presented. A novel role for the established cold thermosensor, TRPM8, as a cellular osmosensor was determined. The studies presented establish that TRPM8 is activated by increases in extracellular osmolality and is partially activated at normal physiological osmolalities. Cool temperatures increase the sensitivity of TRPM8 to osmotic stimuli and activation of phospholipase enzymes modulates activation of TRPM8 by hyperosmotic solutions. TRPM8 is expressed within sensory neurons where it functions as the chief detector of increased osmolality in addition to a molecular sensor of cold sensations. The role of TRPM3 as a candidate heat transduction channel is examined. The findings presented demonstrate that recombinantly expressed TRPM3 channels are heat-sensitive and mice lacking functional TRPM3 channels lose a population of heat-activated neurons and have impaired behavioural responses to noxious heat. Moreover, modulation of TRPM3 by intracellular pathways downstream of G-protein coupled receptor activation has been determined. Activation of TRPM3 in sensory neurons is shown to be robustly inhibited by morphine in a predominantly mu-opioid receptor and Gi dependent mechanism. Additionally the role of TRPM3 in several pain states is examined. Finally, this thesis reports on the characterisation of a medium-throughput CGRP release assay for examining activation of TRPA1 natively expressed on the central terminals of dorsal root ganglion neurons. Activation of TRPA1 expressed on spinal cord synaptosomes by a selection of agonists evokes a concentration-dependent release of CGRP which is inhibited by TRPA1 antagonists. The VGCC subtypes important for TRPA1 and depolarisation-induced CGRP release are examined. 2 Acknowledgements I would like to thank Stuart, my primary supervisor for offering me this PhD studentship four years ago and for being such a consistently supportive and encouraging supervisor. I have enjoyed being part of the Bevan lab so much and feel very lucky to have been a member of such a great research team. I would also like to thank David for being an incredible mentor and for always being there to answer my many, many questions. It has been so reassuring to have such expert guidance on tap at all times! I would also like to thank Clive, firstly for his help with behavioural techniques and dissections and secondly for being great company and a fountain of knowledge! I would also like to thank Adrian and Lisa for their help and guidance during my time spent at Lilly. I would like to thank my good friend and fellow lab member, Nisha, for her ability to instil calm and for all of her help both inside and outside of the lab. Thank you for brightening up long lab days and for your unrelenting kindness. I am not sure whether I could have done it without all of your pep talks! I would like to thank Liz, Jack, Julie, Chancie, Emma, Byron and Dave for welcoming me into the Wolfson CARD and for all of those much needed dancing sessions! I would also like to thank Clare and Ed for the essential office tea and biscuit breaks, and discussions on important matters, like the bizarre television programmes of our childhoods. Clare, I can’t believe our four years together has flown by so quickly. Best of luck in your new job, I can’t wait to hear all about it! I would like to thank all of my friends for keeping me sane over the last four years; I couldn’t have done it without you all. I would like to thank my Mum, Dad and sister, Marsha, for their unwavering encouragement and love. I certainly wouldn’t be where I am now without it. Lastly, I would like to thank Neil, for being my best friend and for putting up with me for so long. 3 Table of Contents ABSTRACT ........................................................................................................................................ 2 ACKNOWLEDGEMENTS .................................................................................................................... 3 TABLE OF CONTENTS ........................................................................................................................ 4 TABLE OF FIGURES ........................................................................................................................... 9 TABLE OF TABLES ........................................................................................................................... 11 ABBREVIATIONS AND ACRONYMS ................................................................................................. 12 CHAPTER 1. GENERAL INTRODUCTION ..................................................................................... 15 1.1 INTRODUCTION TO SENSATION.................................................................................................... 16 1.2 THE SOMATOSENSORY NERVOUS SYSTEM ...................................................................................... 16 1.3 THE PRIMARY AFFERENT NEURON ................................................................................................ 16 1.3.1 Sensory nerve modalities ................................................................................................ 17 1.3.2 Primary afferent nerve fibre types.................................................................................. 17 1.3.3 Nociceptive nerve fibres ................................................................................................. 19 1.3.4 Central projections of primary afferent neurons ............................................................ 20 1.4 TRP CHANNELS ....................................................................................................................... 21 1.4.1 Discovery ........................................................................................................................ 22 1.4.2 Sub-families .................................................................................................................... 22 1.4.3 Structure ......................................................................................................................... 22 1.4.4 Mammalian TRP channels .............................................................................................. 23 1.5 THE MOLECULAR BASIS OF SENSATION .......................................................................................... 27 1.5.1 Thermosensation ............................................................................................................ 28 1.5.2 Mechanosensation ......................................................................................................... 35 1.5.3 Osmosensation ............................................................................................................... 38 1.1.1 Chemosensation ............................................................................................................. 39 1.6 PAIN AND INFLAMMATORY SENSITISATION .................................................................................... 41 CHAPTER 2. GENERAL MATERIAL AND METHODS ..................................................................... 43 2.1 CELL CULTURE
Load more

Recommended publications
  • Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
    Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. Author Cabanas, Helene, Muraki, Katsuhiko, Eaton-Fitch, Natalie, Staines, Donald Ross, Marshall- Gradisnik, Sonya Published 2021 Journal Title Frontiers in Immunology Version Version of Record (VoR) DOI https://doi.org/10.3389/fimmu.2021.687806 Copyright Statement © 2021 Cabanas, Muraki, Eaton-Fitch, Staines and Marshall-Gradisnik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Downloaded from http://hdl.handle.net/10072/406897 Griffith Research Online https://research-repository.griffith.edu.au ORIGINAL RESEARCH published: 13 July 2021 doi: 10.3389/fimmu.2021.687806 Potential Therapeutic Benefitof Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment Edited by: Helene Cabanas 1,2*, Katsuhiko Muraki 2,3, Natalie Eaton-Fitch 1,2, Donald Ross Staines 1,2 Jorge Matias-Guiu, 1,2 Complutense University and Sonya Marshall-Gradisnik
    [Show full text]
  • The Creation of Neuroscience
    The Creation of Neuroscience The Society for Neuroscience and the Quest for Disciplinary Unity 1969-1995 Introduction rom the molecular biology of a single neuron to the breathtakingly complex circuitry of the entire human nervous system, our understanding of the brain and how it works has undergone radical F changes over the past century. These advances have brought us tantalizingly closer to genu- inely mechanistic and scientifically rigorous explanations of how the brain’s roughly 100 billion neurons, interacting through trillions of synaptic connections, function both as single units and as larger ensem- bles. The professional field of neuroscience, in keeping pace with these important scientific develop- ments, has dramatically reshaped the organization of biological sciences across the globe over the last 50 years. Much like physics during its dominant era in the 1950s and 1960s, neuroscience has become the leading scientific discipline with regard to funding, numbers of scientists, and numbers of trainees. Furthermore, neuroscience as fact, explanation, and myth has just as dramatically redrawn our cultural landscape and redefined how Western popular culture understands who we are as individuals. In the 1950s, especially in the United States, Freud and his successors stood at the center of all cultural expla- nations for psychological suffering. In the new millennium, we perceive such suffering as erupting no longer from a repressed unconscious but, instead, from a pathophysiology rooted in and caused by brain abnormalities and dysfunctions. Indeed, the normal as well as the pathological have become thoroughly neurobiological in the last several decades. In the process, entirely new vistas have opened up in fields ranging from neuroeconomics and neurophilosophy to consumer products, as exemplified by an entire line of soft drinks advertised as offering “neuro” benefits.
    [Show full text]
  • 1 TRP About Online
    a TR P to Spain International Workshop on Transient Receptor Potential Channels 12th – 14th September 2012 Valencia, Spain www.trp2012.com SCHEDULE and ABSTRACTS BOOK September 2012 Dear participants, Travelling to faraway places in search of spiritual or cultural enlightenment is a millennium old human activity. In their travels, pilgrims brought with them news, foods, music and traditions from distant lands. This friendly exchange led to the cultural enrichment of visitors and the economic flourishing of places, now iconic, such as Rome, Santiago, Jerusalem, Mecca, Varanasi or Angkor Thom. The dissemination of science and technology also benefited greatly from these travels to remote locations. The new pilgrims of the Transient Receptor Potential (TRP) community are also very fond of travelling. In the past years they have gathered at various locations around the globe: Breckenridge (USA), Eilat (Israel), Stockholm (Sweden) and Leuven (Belgium) come to mind. These meetings, each different and exciting, have been very important for the dissemination of TRP research. We are happy to welcome you in Valencia (Spain) for TRP2012. The response to our call has been extraordinary, surpassing all our expectations. The speakers, the modern bards, readily attended our request to communicate their new results. At last count we were already more than 170 participants, many of them students, and most presenting their recent work in the form of posters or short oral presentations. At least 25 countries are sending TRP ambassadors to Valencia, making this a truly international meeting. We like to thank the staff of the Cátedra Santiago Grisolía, Fundación Ciudad de las Artes y las Ciencias for their dedication and excellence in handling the administrative details of the workshop.
    [Show full text]
  • Therapeutic Targets for the Treatment of Chronic Cough
    Therapeutic Targets for the Treatment of Chronic Cough Roe, N., Lundy, F., Litherland, G. J., & McGarvey, L. (2019). Therapeutic Targets for the Treatment of Chronic Cough. Current Otorhinolaryngology Reports. https://doi.org/10.1007/s40136-019-00239-9 Published in: Current Otorhinolaryngology Reports Document Version: Publisher's PDF, also known as Version of record Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal Publisher rights Copyright 2019 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited. General rights Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [email protected]. Download date:25. Sep. 2021 Current Otorhinolaryngology Reports https://doi.org/10.1007/s40136-019-00239-9 CHRONIC COUGH (K ALTMAN, SECTION EDITOR) Therapeutic Targets for the Treatment of Chronic Cough N.
    [Show full text]
  • Therapeutic Targets for the Treatment of Chronic Cough
    Current Otorhinolaryngology Reports https://doi.org/10.1007/s40136-019-00239-9 CHRONIC COUGH (K ALTMAN, SECTION EDITOR) Therapeutic Targets for the Treatment of Chronic Cough N. A. Roe1 & F. T. Lundy1 & G. J. Litherland2 & L. P. A. McGarvey1 # The Author(s) 2019 Abstract Purpose of Review Chronic cough, defined in adults as one lasting longer than 8 weeks, is among the commonest clinical problems encountered by doctors both in general practice and in hospital. It can exist as a distinct clinical problem or as a prominent and troublesome symptom for patients with common pulmonary conditions including asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Recent Findings Chronic cough impacts considerably on patients’ daily-life activities and many patients are left frustrated by what they see as a complete lack of awareness among their doctors as how to treat their condition. Some of this arises from limited levels of physician knowledge about managing cough as a clinical problem but also because there are no very effective treatments that specifically target cough. Summary In this article, we review the current clinical thinking regarding cough and the treatments that are currently used and those undergoing clinical development. Keywords Cough . Cough receptor . Pharmacological targets . Novel . Ion channel Introduction and is likely due to a slowly resolving post-viral cough. In adult patients, a cough persisting for more than 8 weeks is Under normal physiological circumstances, coughing occurs termed ‘chronic’ and can occur as an isolated clinical problem with the primary purpose of protecting the lung from inhaled or associated with common respiratory and non-respiratory irritants and clearing unwanted airway secretions.
    [Show full text]
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors
    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
    [Show full text]
  • The TRPV4 Agonist GSK1016790A Regulates the Membrane Expression of TRPV4 Channels
    ORIGINAL RESEARCH published: 23 January 2019 doi: 10.3389/fphar.2019.00006 The TRPV4 Agonist GSK1016790A Regulates the Membrane Expression of TRPV4 Channels Sara Baratchi 1*, Peter Keov 1,2,3, William G. Darby 1, Austin Lai 1, Khashayar Khoshmanesh 4, Peter Thurgood 4, Parisa Vahidi 1, Karin Ejendal 5 and Peter McIntyre 1 1 School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia, 2 Molecular Pharmacology Division, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia, 3 St Vincent’s Clinical School, University of New South Wales, Darlinghurst, NSW, Australia, 4 School of Engineering, RMIT University, Melbourne, VIC, Australia, 5 Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, United States TRPV4 is a non-selective cation channel that tunes the function of different tissues including the vascular endothelium, lung, chondrocytes, and neurons. GSK1016790A is the selective and potent agonist of TRPV4 and a pharmacological tool that is used to study the TRPV4 physiological function in vitro and in vivo. It remains unknown how the sensitivity of TRPV4 to this agonist is regulated. The spatial and temporal dynamics of receptors are the major determinants of cellular responses to stimuli. Membrane Edited by: Hugues Abriel, translocation has been shown to control the response of several members of the transient University of Bern, Switzerland receptor potential (TRP) family of ion channels to different stimuli. Here, we show that 2+ Reviewed by: TRPV4 stimulation with GSK1016790A caused an increase in [Ca ]i that is stable for Osama F. Harraz, a few minutes. Single molecule analysis of TRPV4 channels showed that the density University of Vermont, United States Irene Frischauf, of TRPV4 at the plasma membrane is controlled through two modes of membrane Johannes Kepler University of Linz, trafficking, complete, and partial vesicular fusion.
    [Show full text]
  • Development and Application of a High-Throughput Luminescent Prophage Induction Assay for the Identification of Temperate Bacter
    Development and application of a high-throughput luminescent prophage induction assay for the identification of temperate bacteriophage-inducing food-grade compounds By Elizabeth Tompkins Food Science and Agricultural Chemistry, McGill University, Sainte-Anne-de-Bellevue, Quebec April 2019 A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Master of Science in Food Science © Elizabeth Tompkins 2019 Table of Contents Abstract ...........................................................................................................................vi Résumé ......................................................................................................................... viii Acknowledgements .........................................................................................................xi Contribution of authors .................................................................................................. xiii List of tables ...................................................................................................................xv List of figures ................................................................................................................. xvi List of abbreviations ..................................................................................................... xvii Chapter 1: Introduction .................................................................................................... 1 1.1 General introduction .............................................................................................
    [Show full text]
  • Deutsche Gesellschaft Für Experimentelle Und Klinische Pharmakologie Und Toxikologie E.V
    Naunyn-Schmiedeberg´s Arch Pharmacol (2013 ) 386 (Suppl 1):S1–S104 D OI 10.1007/s00210-013-0832-9 Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e.V. Abstracts of the 79 th Annual Meeting March 5 – 7, 2013 Halle/Saale, Germany This supplement was not sponsored by outside commercial interests. It was funded entirely by the publisher. 123 S2 S3 001 003 Multitarget approach in the treatment of gastroesophagel reflux disease – Nucleoside Diphosphate Kinase B is a Novel Receptor-independent Activator of comparison of a proton-pump inhibitor with STW 5 G-protein Signaling in Clinical and Experimental Atrial Fibrillation Abdel-Aziz H.1,2, Khayyal M. T.3, Kelber O.2, Weiser D.2, Ulrich-Merzenich G.4 Abu-Taha I.1, Voigt N.1, Nattel S.2, Wieland T.3, Dobrev D.1 1Inst. of Pharmaceutical & Medicinal Chemistry, University of Münster Pharmacology, 1Universität Duisburg-Essen Institut für Pharmakologie, Hufelandstr. 55, 45122 Essen, Hittorfstr 58-62, 48149 Münster, Germany Germany 2Steigerwald Arzneimittelwerk Wissenschaft, Havelstr 5, 64295 Darmstadt, Germany 2McGill University Montreal Heart Institute, 3655 Promenade Sir-William-Osler, Montréal 3Faculty of Pharmacy, Cairo University Pharmacology, Cairo Egypt Québec H3G 1Y6, Canada 4Medizinische Poliklinik, University of Bonn, Wilhelmstr. 35-37, 53111 Bonn, Germany 3Medizinische Fakultät Mannheim der Universität Heidelberg Institutes für Experimentelle und Klinische Pharmakologie und Toxikologie, Maybachstr. 14, 68169 Gastroesophageal reflux disease (GERD) was the most common GI-diagnosis (8.9 Mannheim, Germany million visits) in the US in 2012 (1). Proton pump inhibitors (PPI) are presently the mainstay of therapy, but in up to 40% of the patients complete symptom control fails.
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • Transient Receptor Potential Vanilloid 4 Channel Deficiency Aggravates Tubular Damage After Acute Renal Ischaemia Reperfusion
    www.nature.com/scientificreports OPEN Transient Receptor Potential Vanilloid 4 Channel Defciency Aggravates Tubular Damage after Received: 29 March 2017 Accepted: 5 March 2018 Acute Renal Ischaemia Reperfusion Published: xx xx xxxx Marwan Mannaa1, Lajos Markó2, András Balogh2,3,4, Emilia Vigolo5, Gabriele N’diaye2, Mario Kaßmann1, Laura Michalick6, Ulrike Weichelt6, Kai M. Schmidt–Ott5, Wolfgang B. Liedtke7, Yu Huang8,9, Dominik N. Müller 2,5, Wolfgang M. Kuebler6 & Maik Gollasch1,2 Transient receptor potential vanilloid 4 (TRPV4) cation channels are functional in all renal vascular segments and mediate endothelium-dependent vasorelaxation. Moreover, they are expressed in distinct parts of the tubular system and activated by cell swelling. Ischaemia/reperfusion injury (IRI) is characterized by tubular injury and endothelial dysfunction. Therefore, we hypothesised a putative organ protective role of TRPV4 in acute renal IRI. IRI was induced in TRPV4 defcient (Trpv4 KO) and wild–type (WT) control mice by clipping the left renal pedicle after right–sided nephrectomy. Serum creatinine level was higher in Trpv4 KO mice 6 and 24 hours after ischaemia compared to WT mice. Detailed histological analysis revealed that IRI caused aggravated renal tubular damage in Trpv4 KO mice, especially in the renal cortex. Immunohistological and functional assessment confrmed TRPV4 expression in proximal tubular cells. Furthermore, the tubular damage could be attributed to enhanced necrosis rather than apoptosis. Surprisingly, the percentage of infltrating granulocytes and macrophages were comparable in IRI–damaged kidneys of Trpv4 KO and WT mice. The present results suggest a renoprotective role of TRPV4 during acute renal IRI. Further studies using cell–specifc TRPV4 defcient mice are needed to clarify cellular mechanisms of TRPV4 in IRI.
    [Show full text]
  • TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS from Basic Science to Clinical Use
    TRP CHANNELS AS THERAPEUTIC TARGETS TRP CHANNELS AS THERAPEUTIC TARGETS From Basic Science to Clinical Use Edited by ARPAD SZALLASI MD, PHD Department of Pathology, Monmouth Medical Center, Long Branch, NJ, USA AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 125 London Wall, London, EC2Y 5AS, UK 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK First published 2015 Copyright © 2015 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher’s permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein). Notices Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein.
    [Show full text]